- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1849KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 371KB)
Ravulizumab – July 2021
Ravulizumab: Solution concentrate for I.V. infusion 300 mg in 3 mL, Solution concentrate for I.V. infusion 1,100 mg in 11 mL; Ultomiris®
Last updated
29 October 2021